NASDAQ:DOVADova Pharmaceuticals Stock Price, Forecast & News Notice: This company has been marked as potentially delisted and may not be actively trading. Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Dova Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add Add Compare Share Today's Range N/A50-Day Range$28.04MA: $28.04▼$28.0452-Week Range N/AVolume35,036 shsAverage Volume499,313 shsMarket Capitalization$807.55 millionP/E RatioN/ADividend YieldN/ABeta2.74 ProfileAnalyst RatingsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Dova Pharmaceuticals, Inc., a pharmaceutical company, focuses on acquiring, developing, and commercializing drug candidates for thrombocytopenia disease. The company's lead product candidate is DOPTELET that is indicated for the treatment of thrombocytopenia in adult patients with chronic liver disease scheduled to undergo a procedure. It also develops DOPTELET for the treatment of chronic immune thrombocytopenia and chemotherapy-induced thrombocytopenia. Dova Pharmaceuticals, Inc. was founded in 2016 and is headquartered in Durham, North Carolina.Read More Beat the Market (BTM) Rank™ 3.2 Analyst's Opinion Consensus RatingDova Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, 4 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $26.42, Dova Pharmaceuticals has a potential upside of ∞ from its current price of $0.00.Amount of Analyst CoverageDova Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesDova Pharmaceuticals has received 231 “outperform” votes. (Add your “outperform” vote.)Underperform VotesDova Pharmaceuticals has received 231 “underperform” votes. (Add your “underperform” vote.)Community SentimentDova Pharmaceuticals has received 50.00% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Dova Pharmaceuticals and other stocks. Vote “Outperform” if you believe DOVA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe DOVA will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldDova Pharmaceuticals does not currently pay a dividend.Dividend GrowthDova Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Dova Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders60.30% of the stock of Dova Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 33.03% of the stock of Dova Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Dova Pharmaceuticals are expected to grow in the coming year, from ($2.44) to ($1.80) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Dova Pharmaceuticals is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Dova Pharmaceuticals is -10.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next Analyst Opinion: 3.2Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.46 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DOVA Previous Symbol CUSIPN/A CIK1685071 Webwww.dova.com Phone919-748-5975Debt Debt-to-Equity Ratio0.41 Current Ratio5.64 Quick Ratio5.37Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$10.35 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$2.71 per share Price / BookN/AProfitability EPS (Most Recent Fiscal Year)($2.60) Net Income$-72,280,000.00 Net Margins-544.09% Return on Equity-101.60% Return on Assets-67.21%Miscellaneous Employees115 Outstanding Shares28,800,000Market Cap$807.55 million Next Earnings DateN/A OptionableOptionable Receive DOVA News and Ratings via Email Sign-up to receive the latest news and ratings for DOVA and its competitors with MarketBeat's FREE daily newsletter. Dova Pharmaceuticals (NASDAQ:DOVA) Frequently Asked Questions Do Wall Street analysts recommend investors buy shares of Dova Pharmaceuticals? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Dova Pharmaceuticals in the last year. There are currently 4 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Dova Pharmaceuticals. How were Dova Pharmaceuticals' earnings last quarter? Dova Pharmaceuticals Inc (NASDAQ:DOVA) posted its quarterly earnings results on Tuesday, August, 6th. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.57) by $0.03. The firm had revenue of $3.52 million for the quarter, compared to the consensus estimate of $5.63 million. Dova Pharmaceuticals had a negative return on equity of 101.60% and a negative net margin of 544.09%. View Dova Pharmaceuticals' earnings history. What price target have analysts set for DOVA? 6 equities research analysts have issued twelve-month price objectives for Dova Pharmaceuticals' stock. Their forecasts range from $15.00 to $30.00. On average, they anticipate Dova Pharmaceuticals' share price to reach $26.42 in the next twelve months. View analysts' price targets for Dova Pharmaceuticals. Has Dova Pharmaceuticals been receiving favorable news coverage? News coverage about DOVA stock has trended extremely negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Dova Pharmaceuticals earned a news impact score of -4.5 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news aboutDova Pharmaceuticals. Who are some of Dova Pharmaceuticals' key competitors? Some companies that are related to Dova Pharmaceuticals include PTC Therapeutics (PTCT), Axsome Therapeutics (AXSM), Arena Pharmaceuticals (ARNA), HUTCHISON CHINA/S (HCM), Uniqure (QURE), Amarin (AMRN), Alkermes (ALKS), Intercept Pharmaceuticals (ICPT), Taro Pharmaceutical Industries (TARO), Apellis Pharmaceuticals (APLS), TG Therapeutics (TGTX), Insmed (INSM), Ra Pharmaceuticals (RARX), Karuna Therapeutics (KRTX) and Principia Biopharma (PRNB). View all competitors. What other stocks do shareholders of Dova Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Dova Pharmaceuticals investors own include Arrowhead Pharmaceuticals (ARWR), Global Blood Therapeutics (GBT), Sasol (SSL), Aldeyra Therapeutics (ALDX), TESARO (TSRO), TherapeuticsMD (TXMD), Allena Pharmaceuticals (ALNA), Fate Therapeutics (FATE), Heron Therapeutics (HRTX) and Immunomedics (IMMU). Who are Dova Pharmaceuticals' key executives? Dova Pharmaceuticals' management team includes the following people: Dr. David S. Zaccardelli, Pres & CEO (Age 54)Mr. Mark W. Hahn, CFO & Sec. (Age 56)Mr. Kevin Laliberte, Sr. VP of Product Devel. (Age 41)Mr. Jason Levine, VP of MarketingMr. Ilija Zlatar, Head of U.S. Sales When did Dova Pharmaceuticals IPO? (DOVA) raised $66 million in an initial public offering (IPO) on Thursday, June 29th 2017. The company issued 4,100,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Leerink Partners acted as the underwriters for the IPO. What is Dova Pharmaceuticals' stock symbol? Dova Pharmaceuticals trades on the NASDAQ under the ticker symbol "DOVA." How big of a company is Dova Pharmaceuticals? Dova Pharmaceuticals has a market capitalization of $0.00 and generates $10.35 million in revenue each year. The company earns $-72,280,000.00 in net income (profit) each year or ($2.60) on an earnings per share basis. Dova Pharmaceuticals employs 115 workers across the globe. What is Dova Pharmaceuticals' official website? The official website for Dova Pharmaceuticals is www.dova.com. How can I contact Dova Pharmaceuticals? Dova Pharmaceuticals' mailing address is 240 Leigh Farm Road Suite 245, Durham NC, 27707. The company can be reached via phone at 919-748-5975 or via email at [email protected] This page was last updated on 5/25/2020 by MarketBeat.com Staff
